Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Group 1 - Gilead Sciences (GILD) stock closed at $92.38, with a daily increase of +1.52%, underperforming the S&P 500's gain of 1.83% [1] - Over the past month, Gilead's shares have decreased by 1.94%, while the Medical sector and S&P 500 have lost 3.48% and 3.31% respectively [1] - The upcoming earnings report on February 11, 2025, is expected to show an EPS of$ 1.67, a decrease of 2.91% year-over-year, with projected revenue of $7.05 billion, reflecting a 0.91% decline [2] Group 2 - Recent analyst estimate revisions indicate near-term business trends, with positive changes suggesting optimism about Gilead's profitability [3] - The Zacks Rank system, which incorporates estimate changes, currently ranks Gilead as 3 (Hold), with a consensus EPS estimate having increased by 0.03% over the past month [4][5] - Gilead's Forward P/E ratio is 12.05, indicating a discount compared to the industry average of 21.47 [6] Group 3 - Gilead has a PEG ratio of 1.28, which is lower than the average PEG ratio of 1.4 for Medical - Biomedical and Genetics stocks [7] - The Medical - Biomedical and Genetics industry holds a Zacks Industry Rank of 60, placing it in the top 24% of over 250 industries, suggesting strong performance potential [8]